ONYX DRUG GETS EUROPEAN APPROVAL

Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. have received the European Commission's authorization to market their kidney cancer drug, the two companies announced. Emeryville-based Onyx and Bayer, based in West Haven, Conn., are codeveloping the drug under an agreement where they share varying costs and profits in different locations. Bayer is commercializing Nexavar in Europe.
Business Times